CLAIMS

1. A compound represented by the formula



(I)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc

are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc

are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

provided that,

(1) when the 1,2-azole ring represented by ring B is

pyrazole, ring C is not thiadiazole or oxadiazole;
(2) when the 1,2-azole ring represented by ring B is isoxazole, ring C is not an optionally substituted pyridone; and
(3) when the 1,2-azole ring represented by ring B is pyrazole and Xa and Xb are each a bond, ring C is not a benzene ring,

or a salt thereof.

2. The compound of claim 1, wherein the ring represented by ring A is an aromatic ring.

3. The compound of claim 2, wherein the aromatic ring is a benzene ring, a pyridine ring or a pyridazine ring.

4. The compound of claim 1, wherein the 1,2-azole ring represented by ring B is pyrazole.

5. The compound of claim 1, wherein the substituent that ring B is optionally further having is a hydrocarbon group.

6. The compound of claim 1, wherein the substituent that ring B is optionally further having is an alkoxy group.

7. The compound of claim 1, wherein Ya is C_{1-6} alkylene or C_{2-6} alkenylene.

8. The compound of claim 1, wherein Xb is -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group).

9. The compound of claim 1, wherein the monocyclic aromatic

ring represented by ring C is a benzene ring.

10. The compound of claim 1, wherein the monocyclic aromatic ring represented by ring C is pyrazole.

11. The compound of claim 1, wherein R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group).

12. The compound of claim 1, wherein Xa is a bond.

13. The compound of claim 1, wherein Xb is -O-.

14. The compound of claim 1, wherein Yb is a bond.

15. The compound of claim 1, wherein Xc is a bond or -O-.

16. The compound of claim 1, wherein Yc is C_{1-6} alkylene or C_{2-6} alkenylene.

17. The compound of claim 1, which is 3-[1-phenyl-3-(4-{3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl}butoxy)-1H-pyrazol-5-yl]propionic acid;
2-[3-(3-{3-ethoxy-1-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-yl}propoxy)phenoxy]-2-methylpropionic acid;
3-[2-ethoxy-4-(3-{3-ethoxy-1-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-yl}propoxy)phenyl]propionic acid;
3-[3-(3-{3-ethoxy-1-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-yl}propoxy)-1-phenyl-1H-pyrazol-5-yl]propionic acid;
[1-phenyl-3-(4-{3-propyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl}butoxy)-1H-pyrazol-4-yl]acetic acid;
[2-(3-{3-isopropyl-1-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-yl}propoxy)-3-methoxyphenyl]acetic acid;
[2-(3-{3-(1-ethylpropyl)-1-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazol-4-yl}propoxy)-3-methoxyphenyl]acetic acid;
(2-{3-[1-(5-chloro-2-pyridyl)-3-(1-ethylpropyl)-1H-pyrazol-4-

yl]propoxy}-3-methoxyphenyl)acetic acid;
[3-ethyl-2-(3-{3-isopropyl-1-[6-(trifluoromethyl)pyridazin-3-yl]-1H-pyrazol-4-yl}propoxy)phenyl]acetic acid;
[2-(3-{3-isopropyl-1-[6-(trifluoromethyl)pyridazin-3-yl]-1H-pyrazol-4-yl}propoxy)-3-methoxyphenyl]acetic acid;
[3-(3-{3-isopropyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl}propoxy)-1-methyl-1H-pyrazol-4-yl]acetic acid;
[1-ethyl-5-(3-{3-isopropyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl}propoxy)-1H-pyrazol-4-yl]acetic acid;
[1-ethyl-5-(3-{3-propyl-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl}propoxy)-1H-pyrazol-4-yl]acetic acid;
(2-{3-[1-(5-bromo-2-pyridinyl)-3-(1-ethylpropyl)-1H-pyrazol-4-yl]propoxy}-3-methoxyphenyl)acetic acid; or
[2-(3-{3-tert-butyl-1-[6-(trifluoromethyl)pyridazin-3-yl]-1H-pyrazol-4-yl}propoxy)-3-methylphenyl]acetic acid.

18. A prodrug of the compound of claim 1 or a salt thereof.

19. A pharmaceutical composition comprising the compound of claim 1 or a salt thereof or a prodrug thereof.

20. An agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by the formula



(Ia)

wherein
ring A is a ring optionally having 1 to 3 substituents;
ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;
Xa, Xb and Xc
are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$

or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof.

21. An agent for the prophylaxis or treatment of hyperlipidemia, which comprises a compound represented by the formula



(Ia)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc are the same or different and each is a bond, -O-,

-S-, -SO-, -SO_2-, -CO-, -CS-, -$CR^1(OR^2)$-, -NR^3-, -$CONR^3$- or -NR^3CO- (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents -OR^4 (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or -NR^5R^6 (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof.

22. An agent for the prophylaxis or treatment of arteriosclerosis, which comprises a compound represented by the formula



(Ib)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc

are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

provided that, when the 1,2-azole ring represented by ring B is isoxazole, ring C is not an optionally substituted pyridone,

or a salt thereof or a prodrug thereof.

23. An agent for the prophylaxis or treatment of impaired glucose tolerance, which comprises a compound represented by the formula



(Ia)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof.

24. A retinoid-related receptor function regulating agent, which comprises a compound represented by the formula



(Ia)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc

are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc

are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof.

25. The agent of claim 24, which is a peroxisome proliferator-activated receptor ligand.

26. The agent of claim 24, which is a retinoid X receptor ligand.

27. An insulin resistance improving agent, which comprises a

compound represented by the formula



(Ia)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc

are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc

are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof.

28. A method for the prophylaxis or treatment of diabetes in a

mammal in need thereof, which comprises administering to the mammal a compound represented by the formula



(Ia)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc

are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc

are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof.

29. Use of a compound represented by the formula



(Ia)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is a 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc

are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or a hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc

are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof, for the production of an agent for the prophylaxis or treatment of diabetes.

30. A GPR40 receptor function modulator comprising a compound represented by the formula



(Ia)

wherein

ring A is a ring optionally having 1 to 3 substituents;

ring B is 1,2-azole ring optionally further having 1 to 3 substituents;

Xa, Xb and Xc are the same or different and each is a bond, -O-, -S-, -SO-, $-SO_2-$, -CO-, -CS-, $-CR^1(OR^2)-$, $-NR^3-$, $-CONR^3-$ or $-NR^3CO-$ (R^1 is a hydrogen atom or an optionally substituted hydrocarbon group, R^2 is a hydrogen atom or hydroxy-protecting group, and R^3 is a hydrogen atom, an optionally substituted hydrocarbon group or an amino-protecting group);

Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms;

ring C is a monocyclic aromatic ring optionally further having 1 to 3 substituents; and

R represents $-OR^4$ (R^4 is a hydrogen atom or an optionally substituted hydrocarbon group) or $-NR^5R^6$ (R^5 and R^6 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^5 and R^6 form, together with the adjacent nitrogen atom, an optionally substituted heterocyclic ring),

or a salt thereof or a prodrug thereof.

31. A production method of a compound represented by the formula



(I-5)

wherein the symbols in the formula are as defined in claim 1, or a salt thereof, which comprises subjecting a compound represented by the formula



(I-4)

wherein R^{12} is an optionally substituted hydrocarbon group and other symbols are as defined above, or a salt thereof to a hydrolysis reaction.

32. A production method of a compound represented by the formula



(II-1)

wherein n is an integer of 0 to 5 and other symbols are as defined in claim 1, or a salt thereof, which comprises subjecting a compound represented by the formula



(VIII)

wherein R^{11} is CHO or $COOR^{13}$ (R^{13} is an alkyl group having 1-6 carbon atoms), and other symbols are as defined above, or a salt thereof to a reduction reaction.

33. A compound represented by the formula



(IX)

wherein n is an integer of 0 to 5, R^{13a} is CH_2OH, CHO or $COOR^{14}$ (R^{14} is an alkyl group having 1-6 carbon atoms), and other symbols are as defined in claim 1, or a salt thereof.